Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older

NCT01732627 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

301

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningitis
Meningococcal Meningitis
Meningococcal Infections
Invasive Meningococcal Disease

Interventions

BIOLOGICAL: Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine
BIOLOGICAL: Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined

Sponsor

Sanofi Pasteur, a Sanofi Company